Literature DB >> 25660289

Absolute configuration of podophyllotoxone and its inhibitory activity against human prostate cancer cells.

Juan Li1, Juan Feng2, Cheng Luo3, Ho-Yung Sung Herman4, Ren-Wang Jiang5.   

Abstract

Podophyllotoxone (1) was isolated from the roots of Dysosma versipellis. The structure was determined by spectroscopic analysis in combination with single-crystal X-ray analysis. The absolute configuration of compound 1 was assigned based on the Flack parameter. It showed significant inhibitory activities against human prostate cancer cells PC3 and DU145 with IC50 values being 14.7 and 20.6 μmol·L(-1), respectively. It also arrested the cells at G2/M phase. Tubulin polymerization assay showed that it inhibited the tubulin polymerization in a dose-dependent manner, and molecular docking analysis revealed a different binding mode with tubulin as compared with those known tubulin inhibitors.
Copyright © 2015 China Pharmaceutical University. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Absolute configuration; Molecular docking; Podophyllotoxone; Prostate cancer; Tubulin

Mesh:

Substances:

Year:  2015        PMID: 25660289     DOI: 10.1016/S1875-5364(15)60007-3

Source DB:  PubMed          Journal:  Chin J Nat Med        ISSN: 1875-5364


  3 in total

1.  Mining Therapeutic Efficacy from Treasure Chest of Biodiversity and Chemodiversity: Pharmacophylogeny of Ranunculales Medicinal Plants.

Authors:  Da-Cheng Hao; Li-Jia Xu; Yu-Wei Zheng; Huai-Yu Lyu; Pei-Gen Xiao
Journal:  Chin J Integr Med       Date:  2022-07-09       Impact factor: 2.626

2.  Dysosma versipellis Extract Inhibits Esophageal Cancer Progression through the Wnt Signaling Pathway.

Authors:  Yanchun Pu; Ping Jin; Lianghong Liu; Qinlin Pu; Fangping Wu
Journal:  Evid Based Complement Alternat Med       Date:  2021-10-20       Impact factor: 2.629

3.  Baicalein induces cervical cancer apoptosis through the NF-κB signaling pathway.

Authors:  Xiaolan Yu; Yuqing Liu; Yongzhou Wang; Xiguan Mao; Yujiao Zhang; Jiyi Xia
Journal:  Mol Med Rep       Date:  2018-01-25       Impact factor: 2.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.